Thymosin Alpha-1

Thymosin Alpha-1 is a peptide whose scientific history spans more than half a century. In 1972 Allan Goldstein and colleagues at Albert Einstein College of Medicine isolated a series of biologically active fractions from bovine thymus tissue that they called 'thymosin fraction 5'. The most active component was purified, sequenced, and named thymosin alpha-1 — a 28-amino-acid N-acetylated peptide. It was later shown to be a naturally occurring proteolytic product of prothymosin alpha, a widely expressed nuclear protein whose fragments serve immunomodulatory functions outside the cell. That combination of natural occurrence and specific immunological effect made it a leading candidate for pharmaceutical development.

Chemically the molecule is a straight 28-amino-acid peptide (SDAAVDTSSEITTKDLKEKKEVVEEAEN) with an acetylated N-terminus. Its mechanism has been progressively refined. Rather than acting as a hormone-like ligand of a single receptor, it appears to function as a Toll-like receptor 2 and Toll-like receptor 9 co-agonist on dendritic cells, driving those cells' maturation into an antigen-presenting phenotype that skews subsequent T-cell responses toward Th1. That downstream effect — improved cellular immunity, enhanced natural killer cell activity, better response to viral antigens — is what underpins its approved uses in chronic viral hepatitis and immunodeficient states.

The regulatory picture is where the compound's identity becomes complicated. Thymalfasin has been authorised as a prescription medicine under the trade name Zadaxin (SciClone Pharmaceuticals) in more than 35 countries — Italy authorised it in 1994 for chronic hepatitis B; subsequent authorisations followed in China, Argentina, Brazil, Mexico, the Philippines, Singapore, and many others. The indication set varies by country and includes chronic hepatitis B, adjunctive treatment of chronic hepatitis C, immune restoration in immunocompromised patients, and — in some jurisdictions — vaccine-response enhancement. Notably, thymalfasin has never received FDA approval in the United States and has not been authorised via the EMA centralised procedure. The compound therefore has one of the most geographically uneven approval footprints in this catalog.

That regulatory geography has consequences for the practical picture. In the countries where Zadaxin is approved, it is a manufactured pharmaceutical with a defined label, standardised dose (typically 1.6 mg subcutaneously twice weekly for chronic hepatitis B), and a decades-long safety record. In countries where it is not approved — including the United States — it is available only through research-supply channels or compounding pharmacies, without the same identity, quality-control, and clinical framework. Consumers who source 'thymosin alpha-1' from grey-market channels are not receiving Zadaxin; they are receiving a peptide of the same chemical identity but a completely different provenance.

Thymosin Alpha-1 is a peptide whose scientific history spans more than half a century. In 1972 Allan Goldstein and colleagues at Albert Einstein College of Medicine isolated a series of biologically active fractions from bovine thymus tissue that they called 'thymosin fraction 5'. The most active component was purified, sequenced, and named thymosin alpha-1 — a 28-amino-acid N-acetylated peptide. It was later shown to be a naturally occurring proteolytic product of prothymosin alpha, a widely expressed nuclear protein whose fragments serve immunomodulatory functions outside the cell. That combination of natural occurrence and specific immunological effect made it a leading candidate for pharmaceutical development.

Chemically the molecule is a straight 28-amino-acid peptide (SDAAVDTSSEITTKDLKEKKEVVEEAEN) with an acetylated N-terminus. Its mechanism has been progressively refined. Rather than acting as a hormone-like ligand of a single receptor, it appears to function as a Toll-like receptor 2 and Toll-like receptor 9 co-agonist on dendritic cells, driving those cells' maturation into an antigen-presenting phenotype that skews subsequent T-cell responses toward Th1. That downstream effect — improved cellular immunity, enhanced natural killer cell activity, better response to viral antigens — is what underpins its approved uses in chronic viral hepatitis and immunodeficient states.

The regulatory picture is where the compound's identity becomes complicated. Thymalfasin has been authorised as a prescription medicine under the trade name Zadaxin (SciClone Pharmaceuticals) in more than 35 countries — Italy authorised it in 1994 for chronic hepatitis B; subsequent authorisations followed in China, Argentina, Brazil, Mexico, the Philippines, Singapore, and many others. The indication set varies by country and includes chronic hepatitis B, adjunctive treatment of chronic hepatitis C, immune restoration in immunocompromised patients, and — in some jurisdictions — vaccine-response enhancement. Notably, thymalfasin has never received FDA approval in the United States and has not been authorised via the EMA centralised procedure. The compound therefore has one of the most geographically uneven approval footprints in this catalog.

That regulatory geography has consequences for the practical picture. In the countries where Zadaxin is approved, it is a manufactured pharmaceutical with a defined label, standardised dose (typically 1.6 mg subcutaneously twice weekly for chronic hepatitis B), and a decades-long safety record. In countries where it is not approved — including the United States — it is available only through research-supply channels or compounding pharmacies, without the same identity, quality-control, and clinical framework. Consumers who source 'thymosin alpha-1' from grey-market channels are not receiving Zadaxin; they are receiving a peptide of the same chemical identity but a completely different provenance.

The foundational discovery paper is Goldstein et al. PNAS 1972, which reported isolation of the biologically active fraction 5 from bovine thymus and characterised the immune-restoring activity. Subsequent purification and sequencing produced the 28-amino-acid molecule now called thymosin alpha-1.

The chronic hepatitis B evidence base includes Andreone et al. 2001 and subsequent randomised trials in HBeAg-positive patients showing sustained virological response benefit. Chien et al. and others extended the evidence into chronic hepatitis C combination with interferon.

The Wu et al. 2013 Chest publication — a Chinese multicentre randomised trial in septic patients — reported a mortality signal favouring thymosin alpha-1 addition to standard care. The result has not been replicated at scale in Western sepsis protocols, but the trial has been influential in the Chinese approval and use of the compound in ICU practice.

The Camerini and Garaci 2015 review synthesises the mechanistic literature — the TLR2/TLR9 co-agonism on dendritic cells, the Th1 polarisation, the NK activation — into a coherent immunopharmacology framework and is the reference document for readers who want to understand the compound's biology beyond its regulatory footprint.

Thymalfasin (Zadaxin) is an approved medicine in more than 35 countries for chronic hepatitis B, adjunctive treatment of chronic hepatitis C, and related immune-restoration indications. Italy was the first EU member state to authorise it (1994); China, Argentina, Brazil, Mexico, the Philippines, Singapore and others followed. SciClone Pharmaceuticals has been the primary commercial vehicle historically.

The compound has never been FDA-approved and has not received centralised EMA authorisation. That regulatory gap is why the compound is available in the US and much of the EU only through research-supply channels or compounding pharmacies — a very different quality-control framework than the approved-product experience in the countries where Zadaxin is registered.

Post-pandemic there has been growing academic interest in thymosin alpha-1 as an immune modulator in specific acute-care contexts (severe COVID-19, sepsis). Results have been mixed; the compound is not standard of care in Western pandemic guidelines. The Camerini and Garaci 2015 review is a useful consolidating source for the broader immunopharmacology.